文章摘要
陶立生许亚平△ 姚俊薛翠华.埃索美拉唑治疗幽门螺杆菌阳性十二指肠球部溃疡疗效观察[J].,2011,11(18):3494-3496
埃索美拉唑治疗幽门螺杆菌阳性十二指肠球部溃疡疗效观察
Esomeprazole for Duodenal Ulcer with Helicobacter Pylori
  
DOI:
中文关键词: 十二指肠球部溃疡  幽门螺杆菌  埃索美拉唑  兰索拉唑  奥美拉唑
英文关键词: Duodenal ulcer  Helicobacter pylori  Esomeprazole  Lansoprazole  Omeprazole
基金项目:
作者单位
陶立生许亚平△ 姚俊薛翠华 镇江第一人民医院消化科 
摘要点击次数: 922
全文下载次数: 1059
中文摘要:
      目的:比较埃索美拉唑与兰索拉唑、奥美拉唑三联疗法治疗幽门螺杆菌(Hp)阳性十二指肠球部溃疡疗效观察。方法:将84 例Hp 阳性的十二指肠球部溃疡随机分为三组。埃索美拉唑组(28 例):埃索美拉唑20mg+ 阿莫西林1g+ 呋喃唑酮100mg,每日2 次,共7 日,后服用埃索美拉唑20mg,每日一次,共21 天;兰索拉唑组(28 例):兰索拉唑15mg+ 阿莫西林1g+ 呋喃唑酮100mg, 每日2 次,共7 日,后服用兰索拉唑15mg,每日一次,共21 天;奥美拉唑组(28 例):奥美拉唑20mg+ 阿莫西林1g+ 呋喃唑酮 100mg,每日2 次,共7 日,后服用奥美拉唑20mg,每日一次,共21 天。疗效结束4 周后复查胃镜并检测Hp,观察腹痛缓解率、溃 疡愈合率,Hp 根治率及药物不良反应。结果:埃索美拉唑组、兰索拉唑组和奥美拉唑组溃疡愈合率分别为100%,85.7%,82.1%, HP 根治率为85.7%,60.7%,64.3%,埃索美拉唑组溃疡愈合率及Hp 根除率高于兰索拉唑组及奥美拉唑组,差异具有统计学意义 (P<0.05)。兰索拉唑组及奥美拉唑组溃疡愈合率及Hp 根除率无明显差异(P>0.05)。三组用药后不良反应少,具较好的安全性。结 论:埃索美拉唑三联疗法治疗Hp 阳性的消化性溃疡疗效优于兰索拉唑及奥美拉唑三联疗法,值得临床广泛应用。
英文摘要:
      Objective: To compare esomeprazole with lansoprazole, omeprazole triple therapy on duodenal ulcer with Helicobacter pylori. Methods: 84 duodenal ulcer patients with Helicobacter pylori were randomly divided into three groups. Esomeprazole group (28 cases): esomeprazole 20mg + amoxicillin 1g + furazolidone 100mg, 2 times a day for 7 days, then taking esomeprazole 20mg, once daily for 21 days; lansoprazole group (28 cases): lansoprazole 15mg + amoxicillin 1g + furazolidone 100mg, 2 times a day for 7 days, then taking lansoprazole 15mg, once daily for 21 days; Ogilvy pull azole group (28 cases): Omeprazole 20mg + amoxicillin 1g + furazolidone 100mg, 2 times a day for 7 days, then taking omeprazole 20mg, once daily for 21 days. repeated endoscopy and detect Hp, observed rates of abdominal pain relief, ulcer healing rate, Hp cure rates and adverse drug reactions after the end for 4 weeks. Results: Esomeprazole group, lansoprazole group and omeprazole group's ulcer healing rate was 100%, 85.7%, 82.1%, HP cure rate was 85.7%, 60.7%, 64.3%, The Hp eradication rate and ulcer healing rate of esomeprazole group is higher than the lansoprazole group and omeprazole group, the difference was statistically significant (P <0.05). The Hp eradication rate and ulcer healing rate of Lansoprazole group and omeprazole group was no significant difference (P> 0.05). The adverse reactions of three groups were little, with better security. Conclusion: The triple therapy with esomeprazole is superior to the triple therapy of lansoprazole and omeprazole on duodenal ulcer with Helicobacter pylori and is worthy of wider application.
查看全文   查看/发表评论  下载PDF阅读器
关闭